Vertex Pharmaceuticals Incorporated (VRTX), operates as Biotechnology company in the United States, Europe & internationally. It offers transformative medicines for people with serious diseases of different age groups. It comes under Healthcare – Biotech sector & trades as “VRTX” ticker at Nasdaq.
In weekly, it favors bullish sequence & expect rally, while pullback holds above August-2025 low. It favors rally in (III), which will confirm, when it breaks above November-2024 high. Currently, it favors correction in ((2)) in 3 or 7 swings against 8.11.2025 low before next rally.
In weekly, it placed ((I)) at $306.08 high in July-2020 & ((II)) at October-2021 low of $176.36. Above there, it ended (I) of ((III)) at $519.88 high in November-2024 & (II) at $362.50 low in August-2025 low. Within (I), it ended I at $292.75 high, II at $233.01 low, III at $510.63 high, IV at $447.70 low & V at $519.88 high. Within extended III, it placed ((1)) at $324.75 high, ((2)) at $282.21 low, ((3)) at $448.40 high, ((4)) at $391.01 low & ((5)) at $510.63 high.
VRTX - Elliott Wave Latest Weekly View:
Below (I) high, it ended (II) in double three correction. It ended w at $377.85 low in December-2024, x at $519.68 high in March-2025 & y at $362.50 low in August-2025. Above there, it ended ((1)) at $507.92 high & favors pullback in ((2)) in 3 or 7 swings correction. Within ((1)), it ended (1) at $403.58 high, (2) at $374.17 low, (3) at $487.52 high, (4) as flat at $450.67 low & (5) at $507.92 high. It favors downside in (A) of ((2)) & expect minor downside, while bounce fail below $463.78 high. Later it should bounce soon in (B) as connector before another push lower. The next pullback in (C), should hold the trend channel to finish ((2)) before next rally continue. But if it breaks below August-2025 low, it can do double correction in (II) against October-2021 low. Buyers can look to enter the extreme area of (C) in ((2)) correction.
風險提示:本文所述僅代表作者個人觀點,不代表 Followme 的官方立場。Followme 不對內容的準確性、完整性或可靠性作出任何保證,對於基於該內容所採取的任何行為,不承擔任何責任,除非另有書面明確說明。

